Overview

A Phase III Study of KN026 in Combination With HB1801 Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Status:
RECRUITING

Trial end date:
2027-12-16

Target enrollment:

Participant gender:

Summary

This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai JMT-Bio Inc.

Treatments:

Carboplatin
Docetaxel
pertuzumab
Trastuzumab